XML 33 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8
Description of Business and Basis of Presentation - Additional Information (Detail) (USD $)
 1 Months Ended 9 Months Ended 272 Months Ended 1 Months Ended 9 Months Ended 1 Months Ended 1 Months Ended 9 Months Ended 9 Months Ended 1 Months Ended 1 Months Ended
Oct. 31, 2012
Feb. 29, 2012
Feb. 28, 2012
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Dec. 31, 2012
Jun. 30, 2012
May 17, 2012
Mar. 31, 2012
Dec. 31, 2011
May 17, 2012
Other Than Equity
Mar. 31, 2012
Other Than Equity
Mar. 18, 2013
Maximum
At Market Sales Agreement
Nov. 02, 2013
Subsequent Event
Sep. 30, 2013
Mann Group
May 17, 2012
Mann Group
Forward Purchase Contracts
Mar. 31, 2012
Mann Group
Forward Purchase Contracts
Sep. 30, 2013
Mann Group
Forward Purchase Contracts
Equity Component
May 17, 2012
Mann Group
Forward Purchase Contracts
Other Than Equity
Mar. 31, 2012
Mann Group
Forward Purchase Contracts
Other Than Equity
Oct. 31, 2013
Mann Group
Subsequent Event
Sep. 30, 2013
Mann Group
Subsequent Event
Sep. 30, 2013
Senior convertible notes due December 15, 2013
Dec. 31, 2012
Senior convertible notes due December 15, 2013
Dec. 12, 2006
Senior convertible notes due December 15, 2013
Sep. 30, 2013
Notes 9.75% Due in 2019
Subsequent Event
Nov. 02, 2013
Notes 9.75% Due in 2019
Subsequent Event
Sep. 30, 2013
Senior convertible notes due December 31 2019
Jul. 01, 2013
Senior convertible notes due December 31 2019
Tranche One
Jul. 01, 2013
Senior convertible notes due December 31 2019
Milestone Rights
Jul. 01, 2013
Senior convertible notes due December 31 2019
Deerfield
Tranche
Jul. 01, 2013
Senior convertible notes due December 31 2019
Deerfield
Maximum
Jul. 01, 2013
Senior convertible notes due December 31 2019
Deerfield
Tranche One
Jul. 01, 2013
Senior convertible notes due December 31 2019
Deerfield
Milestone Rights
Sep. 30, 2013
Money market funds
Dec. 31, 2012
Money market funds
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                                                                          
Deficit accumulated during the development stage       $ 2,242,819,000   $ 2,242,819,000 $ 2,104,912,000                                                            
Goodwill impairment           151,428,000                                                              
Cash flow from operation since inception       (94,681,000) (91,762,000) (1,690,942,000)                                                              
Principal amount of convertible senior notes                                               115,000,000                          
Senior notes, effective interest rate                                               3.75%   3.75%   9.75%       9.75%          
Senior notes, due date                                               Dec. 15, 2013     Jan. 05, 2020         Dec. 31, 2019          
Cash and cash equivalents       93,803,000 1,765,000 93,803,000 61,840,000       2,681,000                                                    
Available borrowings under loan agreement                             30,100,000                                            
Debt facility periodic principal amount                                                     40,000,000         40,000,000          
Proceeds from exercise warrants       49,170,000   49,170,000                   44,700,000           45,000,000 45,000,000                            
Underwritten public offering, number of shares   35,937,500                                                                      
Underwritten public offering, amount   86,300,000                                                                      
Net proceeds from public offering 86,300,000 80,600,000                                                                      
Number of shares purchased by each warrant   0.6 0.6                                                                    
Warrants exercise price per share 2.60 2.40                                                                      
Warrants, maturity date   2016-02                                                                      
Proceeds from exercise warrants   4,500,000 4,500,000                                                                    
Warrants remained unexercised   47,300,000 47,300,000                         45,000,000                                          
Aggregate offering price of common stock under agreement                           50,000,000                                              
Debt facility principal amount                                               115,000,000 115,000,000 115,000,000     80,000,000     160,000,000   40,000,000      
Number of equal tranches                                                               4          
Proceeds from sale of financial instrument                                                                 90,000,000        
Debt facility initial amount                                                                   40,000,000      
Maturity period of cash equivalents       90 days or less at the time of purchase                                                                  
Cash and cash equivalents       93,800,000   93,800,000 61,800,000                                                         91,100,000 60,800,000
Discount rate                                                           12.00% 17.50%       17.50%    
Market debt rate                                                             12.00%            
Capital stock authorized     31,250,000 309,993,285   309,993,285 286,035,082 31,250,000               31,250,000                                          
Number of Shares that recorded the portion of the derivative instrument representing equity                                     14,700,000                                    
Number of Shares that recorded the portion of the derivative instrument representing outside of equity                               16,500,000                                          
Change in fair value recognized in other income         $ 12,000,000         $ (336,000)                                                      
Risk Free Interest Rate                       0.18% 0.06%             0.08% 0.08%                                
Discount for lack of marketability                 1.67% 1.64%             10.27% 2.57%                                      
Valuation date stock price                       $ 1.69               $ 2.40